20 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 NEWS Veranova is pleased to announce the move of its corporate headquarters to its Devens, Massachusetts facility, one of the company’s principal sites for manufacturing and development. Strategically located near the Boston pharmaceutical and biotech hub, Veranova’s Devens site is an FDA approved facility and a center of excellence for development through clinical and commercial manufacturing of antibody-drug conjugates (ADCs), high potent APIs, phosphoramidites and other complex small molecules. The site is currently undergoing a $30M expansion of its ADC and high potent development and manufacturing capabilities. The investment in Devens is part of a multi-year growth strategy to build the leading development and manufacturing partner for complex synthetic pharmaceuticals, and spans our locations in West Deptford, New Jersey; North Andover, Massachusetts; Edinburgh, Scotland and Cambridge, England. With the re-location of the corporate headquarters, Veranova will be exiting the current headquarters office in Wayne, Pennsylvania. Existing employees in Wayne will continue operating from a new location in Berwyn, Pennsylvania. Veranova relocates headquarters to Devens, MA SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced the expansion of a core competency with the launch of an enhanced analytical testing laboratory specifically dedicated to High Potency Active Pharmaceutical Ingredients (HPAPIs). Located at SK pharmteco’s Rancho Cordova, California site, the stateof-the-art CGMP laboratory is a significant addition to the site’s current HPAPIs’ laboratory operations. Designed for the safe handling of potent chemicals for CGMP testing and release, the lab is now fully operational and has already achieved a significant milestone: the successful release of its first Active Pharmaceutical Ingredient (API). “We are excited to expand our capabilities and provide more efficient testing solutions for our customers,” said Joerg Ahlgrimm, CEO of SK pharmteco. “This expansion underscores our steadfast commitment to safety, innovation, and providing a seamless and customer-centric experience, particularly as compounds under development become increasingly more potent.” The new laboratory builds on the site’s current HPAPI capabilities and provides an increase in a controlled environment for the Quality Control and Analytical Method Development teams to handle highly potent and cytotoxic compounds. In addition to supporting the organization’s small molecule production programs, the laboratory is also available for contract analytical testing services. The laboratory’s notable features include: • Advanced Testing Capabilities: - Equipped to handle Highly Potent Compounds with Occupational Exposure Limits (OEL) to Band 5 - Analytical Weighing - Coulometric & Volumetric Water Titration - UPLC with Diode Array Detection - Headspace & Direct Inject Gas Chromatography with FID Detection • Stringent Containment & Safety Features: - Isolator Glove Box with inertion, washdown, & sample transfer capabilities - Exposure Control down to 0.008 µg/m3 TWA (qualified via independent third-party surrogate testing) - Dedicated HVAC maintaining negative pressure to the antechamber - Sample passthrough port for laboratory isolation - Dedicated gowning & degowning rooms with misting wash down decontamination With decades of experience in scaling HPAPI processes from clinical to commercial production, SK pharmteco brings unmatched expertise and capacity to support customers at every stage of development and reinforces its position as a trusted partner in the pharmaceutical industry, enabling the development and manufacture of lifechanging medicines. SK pharmteco launches state-of-the-art HPAPI laboratory
RkJQdWJsaXNoZXIy MjY2OTA4MA==